key: cord-0838073-pd56aqca authors: Jering, Karola S.; McGrath, Martina M.; Mc Causland, Finnian R.; Claggett, Brian; Cunningham, Jonathan W.; Solomon, Scott D. title: Excess mortality in solid organ transplant recipients hospitalized with COVID‐19: A large‐scale comparison of SOT recipients hospitalized with or without COVID‐19 date: 2021-10-01 journal: Clin Transplant DOI: 10.1111/ctr.14492 sha: f8295d4b2aa53065e0ab462d5699ef8067e29894 doc_id: 838073 cord_uid: pd56aqca BACKGROUND: Solid‐organ transplant (SOT) recipients with coronavirus disease 2019 (COVID‐19) have higher risk of adverse outcomes compared to the general population. Whether hospitalized SOT recipients with COVID‐19 are at higher risk of mortality than SOT recipients hospitalized for other causes, including non‐COVID‐19 pneumonia, remains unclear. METHODS: We used logistic regression to compare outcomes of SOT recipients hospitalized with COVID‐19 to non‐COVID‐19 related admissions and with non‐COVID‐19 pneumonia. RESULTS: Of 17,012 hospitalized SOT recipients, 1682 had COVID‐19. Those with COVID‐19 had higher odds of ICU admission (adjusted odds ratio [aOR] 2.12 [95%CI: 1.88–2.39]) and mechanical ventilation (aOR 3.75 [95%CI: 3.24–4.33]). COVID‐19 was associated with higher odds of in‐hospital death, which was more pronounced earlier in the pandemic (aOR 9.74 [95%CI: 7.08–13.39] for April/May vs. aOR 7.08 [95%CI: 5.62–8.93] for June through November 2020; P‐interaction = .03). Compared to SOT recipients hospitalized with non‐COVID‐19 pneumonia, odds of in‐hospital death were higher in SOT recipients with COVID‐19 (aOR 2.44 [95% CI: 1.90–3.13]), regardless of time of hospitalization (P‐interaction > .40). CONCLUSIONS: In this large cohort of SOT recipients, hospitalization with COVID‐19 was associated with higher odds of complications and in‐hospital mortality than non‐COVID‐19 related admissions, and 2.5‐fold higher odds of in‐hospital mortality, compared to SOT recipients with non‐COVID‐19 pneumonia. Since the first reports of the novel severe acute respiratory syn- Therefore, in this large multi-center cohort study, we hypothesized that SOT recipients hospitalized with COVID-19 would have a higher risk of mechanical ventilation, intensive care admission, and in-hospital mortality, compared to SOT recipients without COVID-19. We further hypothesized that, among hospitalized SOT recipients, COVID-19 would be associated with a higher risk of adverse outcomes, compared with non-COVID-19 related pneumonia. Solid-organ transplant recipients ≥18 years of age who were discharged from inpatient hospitalization between April 1, 2020 and November 30, 2020 were identified within the Premier Healthcare Database by International Classification of Disease, 10 th revision (ICD-10) codes (Table S1 ). COVID-19 status was defined using the ICD-10 code U07.1 (SARS-CoV-2 virus identified) and hospitalization for non-COVID-19 related pneumonia using respective ICD-10 codes (Table S1 ). The Premier Healthcare Database is an all-payer, claims-based database encompassing ∼20% of US hospitalizations. 6 For SOT recipients without a diagnosis of COVID-19, the first hospitalization within the above timeframe was evaluated, and for SOT recipients with COVID-19, only the first hospitalization related to COVID-19 was considered. The primary outcomes of interest were mechanical ventilation, intensive care utilization, and in-hospital mortality. Intensive care was defined using billing codes for intensive care room and board, or daily ventilator management. Secondary outcomes included venous thromboembolic disease (VTE), need for renal replacement therapy, length of stay, and discharge disposition. Outcomes were identified based on billing and ICD-10 diagnosis and procedure codes (Tables S1 and S2 Calcineurin inhibitor use during the hospitalization was more com- Figure 1 . Use of hydroxychloroquine sharply declined over time while use of dexamethasone (in mechanically ventilated patients) and remdesivir increased over the duration of the study. The frequency of mechanical ventilation and ICU admission was significantly higher among SOT recipients with COVID-19, as compared to those without COVID-19 (mechanical ventilation: 20.6% vs. 6 Similar patterns of association were noted in sensitivity analyses that excluded patients admitted electively (Table S4 ). When compared to SOT recipients without COVID-19, SOT recipients with COVID-19 experienced higher in-hospital mortality (17.2% vs. (P = .003) ( Table 2) . Similar patterns of association were noted in sensitivity analyses that excluded patients admitted electively (Table S4 ). Effect estimates are presented as odds ratios (derived from logistic regression models for venous thromboembolism, intensive care, mechanical ventilation, renal replacement therapy, cardiac arrest, in-hospital death) or ratios (derived from negative binomial regression models for length of stay). Reference is SOT recipients without COVID-19. P-interaction refers to test for effect modification of the association of COVID-19 status with outcomes of interest according to month (April/May vs. June to November). a Adjusted for age, sex, race, geographic region, discharge month, obesity, hypertension, diabetes, heart failure, peripheral vascular disease, cerebrovascular disease, chronic kidney disease, chronic lung disease, cancer, and tobacco use. Temporal trends in in-hospital mortality in SOT recipients hospitalized with and without COVID-19. The bar graph shows in-hospital mortality in SOT recipients hospitalized with (red) and without (blue) COVID-19 by month of hospitalization. N refers to the total number of SOT recipients with and without COVID-19, respectively, who were hospitalized and discharged during each respective month Similar patterns of association were noted in sensitivity analyses that excluded patients admitted electively (Table S4 ). Among SOT recipients hospitalized with COVID-19, 64.8% were discharged home, 9.9% were transferred to post-acute care facilities, and 18.6% died or were transferred to hospice (Table 1 ). Hospital length of stay was 61% (95% CI: 54-69%) longer in SOT recipients with COVID-19, as compared to those without COVID-19 after adjustment for demographic and clinical covariates ( Table 2) . Similar patterns of association were noted in sensitivity analyses that excluded patients admitted electively (Table S4 ). Since medical management (e.g., changes in immunosuppression, institution of antimicrobial therapy, and escalation of care) of SOT recipients hospitalized with non-COVID-19 pneumonia may be similar to that of SOT recipients hospitalized with COVID-19, clinical characteristics and in-hospital outcomes were compared among these groups. Effect estimates are presented as odds ratios (derived from logistic regression models for venous thromboembolism, intensive care, mechanical ventilation, cardiac arrest, in-hospital death) or ratios (derived from negative binomial regression models for length of stay). Reference is SOT recipients with non-COVID-19 pneumonia. P-interaction refers to test for effect modification of the association of COVID-19 status with outcomes of interest according to month (April/May vs. June to November). a Adjusted for age, sex, race, geographic region, discharge month, obesity, hypertension, diabetes, heart failure, peripheral vascular disease, cerebrovascular disease, chronic kidney disease, chronic lung disease, cancer, and tobacco use. with mortality. 7 Conversely, the cytokine storm that accompanies the development of severe COVID-19 has led some to postulate that the use of immunosuppression may mitigate against the development of severe disease. 12, 13 However, most reports to date suggest that reduc- COVID-19 infection appears to be associated with a pro-thrombotic tendency, [17] [18] [19] [20] [21] [22] often manifested by development of VTE. 23 In our analyses, the average VTE frequency was 4.3%, which is similar to that reported by Kates et al., 7 but lower than the 9% reported in a study of critically ill SOT recipients. 24 The difference in the latter may be simply attributable to an overall higher risk of such events in critically ill patients. Although we did not find a significant difference in the frequency of VTE between SOT recipients with and without COVID-19, it should be noted that the frequency of anticoagulation use was substantially higher in the group with COVID-19. Multiple prior studies have reported worse outcomes of SOT recipients with COVID-19 as compared with non-SOT recipients. 7, 9, 10 Our analyses address a different and a unique question: comparing The other authors report no conflicts. Research idea and study design: Karola S. Solomon. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Data can be requested from Premier Healthcare. Finnian R. Mc Causland https://orcid.org/0000-0002-0299-0533 Mortality Analyses -Johns Hopkins Coronavirus Resource Center. Accessed: 2020 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Infection in organ transplantation Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19 COVID-19 in solid organ transplant: a multi-center cohort study An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants Is Covid-19 infection more severe in kidney transplant recipients? COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium COVID-19 mortality among kidney transplant candidates is strongly associated with social determinants of health COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal COVID-19 and solid organ transplant outcomes COVID-19 in transplant recipients: the Spanish experience Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center Hematological findings and complications of COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action Prominent changes in blood coagulation of patients with SARS-CoV-2 infection COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States Low immunization rates among kidney transplant recipients who received two doses of the mRNA-1273 SARS-CoV-2 vaccine Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients COVID-19 severity in kidney transplant recipients is similar to non-transplant patients with similar comorbidities Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: a cohort study COVID-19 in solid organ transplant recipients: initial report from the US epicenter Covid-19 and kidney transplantation Excess Mortality in Solid Organ Transplant Recipients Hospitalized with COVID-19: a Large-Scale Comparison of SOT Recipients Hospitalized With or Without COVID-19